An FDA panel that includes several peptide sellers recommended four peptides Thursday and one more Friday for pharmacy compounding, while turning down another.
Recap by typeshit. Full story at The New York Times.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
On his podcast No Appointment Necessary, the NHS GP cites studies suggesting people regain about 60% of lost weight within a year of stopping.
Vomiting fell to 43% from 58.5% on placebo, and Vanda plans to seek an expanded approval for GLP-1 nausea based on the results.
Loading…